Spruce Biosciences, Inc.(SPRB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SPRB Spruce Biosciences, Inc.

盘前交易 10-28 08:37:05 EDT

45.65

+1.66

+3.77%

最高46.90	最低43.74	成交量9.16万
今开43.74	昨收43.99	日振幅7.18%
总市值1.31亿	流通市值1.04亿	总股本287.40万
成交额417.84万	换手率4.00%	流通股本228.65万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":45.65,"timestamp":1793131200000,"preClose":43.99,"halted":0,"volume":91555,"delay":0,"changeRate":0.037735849056603696,"floatShares":2286500,"shares":2874013,"eps":-38.43,"marketStatus":"盘前交易","change":1.66,"latestTime":"10-28 08:37:05 EDT","open":43.74,"high":46.9,"low":43.74,"amount":4178396.886385,"amplitude":0.071835,"askPrice":48.5,"askSize":40,"bidPrice":35.13,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-38.43,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793194200000},"marketStatusCode":1,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":45.65,"postHourTrading":{"tag":"盘后","latestPrice":45.65,"preClose":45.65,"latestTime":"19:30 EDT","volume":3524,"amount":160871.62,"timestamp":1793143800556,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2017331321596236,"impliedVol":0.883,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/SPRB/wiki","defaultTab":"wiki","newsList":[{"id":"1190379439","title":"FDA认可Spruce Biosciences技术转移后的可比性策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1190379439","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190379439?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:06","pubTimestamp":1787573199,"startTime":"0","endTime":"0","summary":"Spruce Biosciences传来最新动态——美国食品药品监督管理局对该公司的可比性策略给出了积极评价，认定这些策略在技术转移后依然合理有效。FDA的认可意味着Spruce所采用的方法论与监管预期高度契合，为公司在研产品的推进扫清了潜在障碍。FDA在评估过程中对Spruce提交的策略进行了全面审视，最终确认其合理性。市场观察人士认为，FDA的这一态度可能为Spruce Biosciences的未来临床试验路径铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162467805","title":"Spruce Biosciences宣布与FDA召开积极的Pre-BLA会议，并确认TA-ERT的BLA提交按计划于2026年第四季度进行","url":"https://stock-news.laohu8.com/highlight/detail?id=1162467805","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162467805?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:05","pubTimestamp":1787573153,"startTime":"0","endTime":"0","summary":"Spruce Biosciences今日宣布，已与美国食品药品监督管理局圆满完成Pre-BLA会议，会议结果积极正面。公司同时确认，其在研药物TA-ERT的生物制剂许可申请提交工作正稳步推进，预计将于2026年第四季度如期完成。通过与FDA的深入沟通，Spruce Biosciences获得了宝贵的监管指导，为后续申请材料的完善与递交奠定了坚实基础。公司管理层对TA-ERT的临床数据及监管路径充满信心，并表示将全力确保BLA申请的高质量提交，以期尽快为患者带来这一潜在的全新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192791549","title":"Spruce Biosciences与FDA就确证性研究设计达成一致；研究或在BLA审评期间启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1192791549","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192791549?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:02","pubTimestamp":1787572964,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc. 与FDA已就确证性研究的设计方案达成一致。值得注意的是，这项研究的启动可能恰逢生物制剂许可申请（BLA）审评阶段。这一进展为公司的临床开发路径增添了新的确定性。双方共识的形成，标志着监管沟通迈出关键一步。业界普遍关注，此举有望加速相关疗法的上市进程。毕竟，在创新药研发的漫长征程中，每一个里程碑都意义非凡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130491594","title":"Spruce Biosciences获Cure Sanfilippo基金会与国家MPS学会550万美元投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1130491594","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130491594?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:03","pubTimestamp":1786536190,"startTime":"0","endTime":"0","summary":"Spruce Biosciences公司迎来重大利好——Cure Sanfilippo基金会与国家MPS学会联合注资550万美元。这笔投资如同强心剂，为这家深耕罕见病领域的生物科技公司注入新动能。两大权威机构与Spruce Biosciences携手，将共同推动疾病研究迈向新高度。资金到账后，研发管线有望加速推进，为患者群体带来更多希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177399003","title":"Spruce Biosciences任命埃里克·乔丹为营销副总裁，蒂娜·古洛塔为财务与公司控制副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1177399003","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177399003?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:01","pubTimestamp":1781524915,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc. 宣布了其高级管理团队的两项重要任命。埃里克·乔丹将出任公司营销副总裁，而蒂娜·古洛塔则被任命为财务与公司控制副总裁。\n此次人事变动旨在加强公司在关键职能领域的领导力。乔丹先生将负责领导公司的全球营销战略，推动品牌发展和市场拓展。古洛塔女士则将全面负责公司的财务运营、报告流程以及内部控制体系。\n这两项任命反映了公司致力于强化其商业运营和财务治理架构，以支持未来的业务增长和战略目标的实现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120948931","title":"Spruce Biosciences发布长期Tralesinidase Alfa酶替代疗法数据，针对B型圣菲利波综合征（MPS IIIB）的研究成果亮相第18届国际MPS研讨会","url":"https://stock-news.laohu8.com/highlight/detail?id=1120948931","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120948931?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:05","pubTimestamp":1780949114,"startTime":"0","endTime":"0","summary":"Spruce Biosciences公司宣布，其针对B型圣菲利波综合征（又称黏多糖贮积症IIIB型，MPS IIIB）的长期Tralesinidase Alfa酶替代疗法数据，已在第18届国际黏多糖贮积症研讨会上正式公布。该数据揭示了该疗法在长期治疗中的表现与潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128975868","title":"Spruce Biosciences任命Brian Walls为市场准入副总裁、Darren Johnson为商业运营副总裁，进一步强化商业领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1128975868","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128975868?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896164,"startTime":"0","endTime":"0","summary":"Spruce Biosciences宣布两项重要高管任命：Brian Walls出任市场准入副总裁，Darren Johnson担任商业运营副总裁。此次人事布局将显著增强公司的商业领导团队实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516632349","title":"Spruce Biosciences, Inc.盘中异动 大幅下挫9.23%报0.353美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516632349?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012321,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Spruce Biosciences, Inc.股票出现异动，股价大幅跳水9.23%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.26%、26.91%、22.55%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Cibus, Inc.，振幅分别为21.22%、19.25%、9.55%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223201abe63345&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223201abe63345&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378974","title":"Spruce Biosciences, Inc.盘中异动 早盘股价大涨6.13%报0.405美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514378974?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:33","pubTimestamp":1740753182,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时33分，Spruce Biosciences, Inc.股票出现波动，股价急速上涨6.13%。截至发稿，该股报0.405美元/股，成交量1.7316万股，换手率0.04%，振幅6.62%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223302abe0eaf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223302abe0eaf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513773326","title":"Spruce Biosciences, Inc.盘中异动 股价大跌5.12%报0.399美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513773326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513773326?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:08","pubTimestamp":1740409726,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时08分，Spruce Biosciences, Inc.股票出现异动，股价快速下挫5.12%。截至发稿，该股报0.399美元/股，成交量9.7834万股，换手率0.24%，振幅3.95%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230847abdb16f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230847abdb16f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513961772","title":"Spruce Biosciences, Inc.盘中异动 早盘股价大跌5.67%报0.401美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513961772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513961772?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148295,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Spruce Biosciences, Inc.股票出现异动，股价大幅下挫5.67%。截至发稿，该股报0.401美元/股，成交量1.7247万股，换手率0.04%，振幅0.00%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223136a24eb02f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223136a24eb02f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512016528","title":"Spruce Biosciences, Inc.盘中异动 股价大跌6.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512016528","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512016528?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:33","pubTimestamp":1739889202,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时33分，Spruce Biosciences, Inc.股票出现波动，股价快速下挫6.04%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Glycomimetics, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为279.48%、96.30%、72.32%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Allogene Therapeutics, Inc.、Solid Biosciences Inc.，振幅分别为34.04%、22.30%、18.61%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223322abd3af9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223322abd3af9e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510671838","title":"Spruce Biosciences, Inc.盘中异动 临近午盘大幅跳水6.19%报0.381美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510671838","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510671838?lang=zh_cn&edition=full","pubTime":"2025-02-11 00:31","pubTimestamp":1739205114,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日00时31分，Spruce Biosciences, Inc.股票出现异动，股价快速下跌6.19%。截至发稿，该股报0.381美元/股，成交量5.3938万股，换手率0.13%，振幅7.20%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211003154abc9bf16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211003154abc9bf16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509660744","title":"Spruce Biosciences, Inc.盘中异动 早盘大幅拉升5.32%报0.400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509660744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509660744?lang=zh_cn&edition=full","pubTime":"2025-02-05 00:14","pubTimestamp":1738685679,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日00时14分，Spruce Biosciences, Inc.股票出现波动，股价快速上涨5.32%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.33%。其相关个股中，Estrella Immunopharma Inc C/Wts 29/09/2028、Azitra Inc、Evaxion Biotech As涨幅较大，Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为1628.21%、924.76%、439.00%，振幅较大的相关个股有Azitra Inc、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Quoin Pharmaceuticals Ltd，振幅分别为72.82%、49.88%、47.29%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205001440a2393cbe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205001440a2393cbe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507496652","title":"Spruce Biosciences, Inc.盘中异动 下午盘股价大跌5.77%报0.358美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507496652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507496652?lang=zh_cn&edition=full","pubTime":"2025-01-30 03:12","pubTimestamp":1738177927,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日03时12分，Spruce Biosciences, Inc.股票出现异动，股价急速下跌5.77%。截至发稿，该股报0.358美元/股，成交量30.6329万股，换手率0.74%，振幅3.95%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.97%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501300312079613b58d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501300312079613b58d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504195546","title":"Spruce Biosciences, Inc.盘中异动 早盘快速下跌6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504195546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504195546?lang=zh_cn&edition=full","pubTime":"2025-01-17 23:54","pubTimestamp":1737129271,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日23时54分，Spruce Biosciences, Inc.股票出现波动，股价快速下挫6.01%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.74%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501172354319607abc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501172354319607abc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503157465","title":"Spruce Biosciences, Inc.盘中异动 快速拉升6.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503157465","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503157465?lang=zh_cn&edition=full","pubTime":"2025-01-14 22:46","pubTimestamp":1736865996,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日22时46分，Spruce Biosciences, Inc.股票出现异动，股价急速拉升6.59%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，Eterna Therapeutics Inc.、Seastar Medical Holding Corp C/Wts 28/10/2027 、Jasper Therapeutics Inc C/Wts 24/09/2026 涨幅较大，Soligenix, Inc.、Phio Pharmaceuticals Corp.、Eterna Therapeutics Inc.较为活跃，换手率分别为364.14%、312.17%、226.00%，振幅较大的相关个股有Eterna Therapeutics Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Soligenix, Inc.，振幅分别为86.57%、34.18%、24.92%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114224636abaab07d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114224636abaab07d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503458798","title":"Spruce Biosciences, Inc.盘中异动 早盘急速下跌5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503458798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503458798?lang=zh_cn&edition=full","pubTime":"2025-01-14 00:07","pubTimestamp":1736784439,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日00时07分，Spruce Biosciences, Inc.股票出现异动，股价大幅下跌5.38%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.02%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为11173.57%、6043.08%、424.28%，振幅较大的相关个股有Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.，振幅分别为336.09%、216.61%、124.54%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140007199602642f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501140007199602642f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501029608","title":"Spruce Biosciences, Inc.盘中异动 大幅下跌6.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501029608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501029608?lang=zh_cn&edition=full","pubTime":"2025-01-07 02:53","pubTimestamp":1736189614,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日02时53分，Spruce Biosciences, Inc.股票出现波动，股价急速跳水6.17%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.41%。其相关个股中，Scisparc Ltd.、Unity Biotechnology, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大，Scisparc Ltd.、Cns Pharmaceuticals, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为1677.26%、383.04%、173.78%，振幅较大的相关个股有Scisparc Ltd.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Ocean Biomedical Inc C/Wts 14/02/2028 ，振幅分别为176.15%、106.67%、92.16%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010702533495faa13d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010702533495faa13d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2495982521","title":"Spruce Biosciences, Inc.盘中异动 早盘股价大跌6.29%报0.410美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495982521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2495982521?lang=zh_cn&edition=full","pubTime":"2024-12-30 23:00","pubTimestamp":1735570804,"startTime":"0","endTime":"0","summary":"北京时间2024年12月30日23时00分，Spruce Biosciences, Inc.股票出现波动，股价急速下跌6.29%。截至发稿，该股报0.410美元/股，成交量9.6756万股，换手率0.23%，振幅5.17%。Spruce Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.26%。Spruce Biosciences, Inc.公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230230004ab982cdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241230230004ab982cdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":0.1072},{"period":"1month","weight":-0.063},{"period":"3month","weight":0.1013},{"period":"6month","weight":-0.2036},{"period":"1year","weight":-0.6289},{"period":"ytd","weight":-0.4759}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0551},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1232},{"period":"ytd","weight":0.1287}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Spruce Biosciences, Inc.最初于2014年11月在特拉华州成立为一家有限责任公司。该公司是一家处于后期阶段的生物制药公司，专注于开发和商业化治疗罕见的内分泌疾病的新疗法，这些疾病的医疗需求尚未得到满足。该公司正在初步开发全资候选产品tildacerfont，作为潜在的第一个非甾体疗法，为患有典型先天性肾上腺增生症的患者提供显著改善的疾病控制和减少类固醇负担。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.190445},{"month":2,"riseRate":0.5,"avgChangeRate":-0.036118},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.209049},{"month":4,"riseRate":0,"avgChangeRate":-0.19428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.048966},{"month":6,"riseRate":0.5,"avgChangeRate":-0.057688},{"month":7,"riseRate":0.5,"avgChangeRate":0.040059},{"month":8,"riseRate":0.5,"avgChangeRate":0.086587},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.142784},{"month":10,"riseRate":0.333333,"avgChangeRate":1.744428},{"month":11,"riseRate":0.5,"avgChangeRate":0.001192},{"month":12,"riseRate":0.333333,"avgChangeRate":0.217863}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Spruce Biosciences, Inc.(SPRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Spruce Biosciences, Inc.(SPRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}